Celonic offers biotech companies use of new GS-CHOvolution cell line expression system
Celonic has signed a commercial license agreement with Revvity for its CHOSOURCE expression platform and TnT transposon technology. The Revvity expression platform will be used in combination with Celonic’s expertise and workflows to enhance the cell line development of monoclonal antibodies (mAbs) and complex proteins.












